Trial · NCT01983553
Results by group344
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 344
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Event Rate Per 100 Participant-years for Hospitalized Virologically-Confirmed Dengue (VCD) Cases Due to Any and Each Serotype Following Vaccination With Either CYD Dengue Vaccine or Placebo in the Previous Study (CYD23) | CYD Dengue Vaccine Group | Any of the 4 Serotypes | 1.0 | 95% Confidence Interval 0.8 to 1.2 | Events per 100 participant-years |
Event Rate Per 100 Participant-years for Hospitalized Virologically-Confirmed Dengue (VCD) Cases Due to Any and Each Serotype Following Vaccination With Either CYD Dengue Vaccine or Placebo in the Previous Study (CYD23) | Control Group | Any of the 4 Serotypes | 1.1 | 95% Confidence Interval 0.8 to 1.4 | Events per 100 participant-years |
Event Rate Per 100 Participant-years for Hospitalized Virologically-Confirmed Dengue (VCD) Cases Due to Any and Each Serotype Following Vaccination With Either CYD Dengue Vaccine or Placebo in the Previous Study (CYD23) | CYD Dengue Vaccine Group | Serotype 1 | 0.2 | 95% Confidence Interval 0.2 to 0.4 | Events per 100 participant-years |
Event Rate Per 100 Participant-years for Hospitalized Virologically-Confirmed Dengue (VCD) Cases Due to Any and Each Serotype Following Vaccination With Either CYD Dengue Vaccine or Placebo in the Previous Study (CYD23) | Control Group | Serotype 1 | 0.3 | 95% Confidence Interval 0.1 to 0.5 | Events per 100 participant-years |
Event Rate Per 100 Participant-years for Hospitalized Virologically-Confirmed Dengue (VCD) Cases Due to Any and Each Serotype Following Vaccination With Either CYD Dengue Vaccine or Placebo in the Previous Study (CYD23) | CYD Dengue Vaccine Group | Serotype 2 | 0.3 | 95% Confidence Interval 0.2 to 0.5 | Events per 100 participant-years |
Event Rate Per 100 Participant-years for Hospitalized Virologically-Confirmed Dengue (VCD) Cases Due to Any and Each Serotype Following Vaccination With Either CYD Dengue Vaccine or Placebo in the Previous Study (CYD23) | Control Group | Serotype 2 | 0.3 | 95% Confidence Interval 0.1 to 0.5 | Events per 100 participant-years |
Event Rate Per 100 Participant-years for Hospitalized Virologically-Confirmed Dengue (VCD) Cases Due to Any and Each Serotype Following Vaccination With Either CYD Dengue Vaccine or Placebo in the Previous Study (CYD23) | CYD Dengue Vaccine Group | Serotype 3 | 0.2 | 95% Confidence Interval 0.2 to 0.4 | Events per 100 participant-years |
Event Rate Per 100 Participant-years for Hospitalized Virologically-Confirmed Dengue (VCD) Cases Due to Any and Each Serotype Following Vaccination With Either CYD Dengue Vaccine or Placebo in the Previous Study (CYD23) | Control Group | Serotype 3 | 0.2 | 95% Confidence Interval 0.1 to 0.4 | Events per 100 participant-years |
Event Rate Per 100 Participant-years for Hospitalized Virologically-Confirmed Dengue (VCD) Cases Due to Any and Each Serotype Following Vaccination With Either CYD Dengue Vaccine or Placebo in the Previous Study (CYD23) | CYD Dengue Vaccine Group | Serotype 4 | 0.2 | 95% Confidence Interval 0.1 to 0.3 | Events per 100 participant-years |
Event Rate Per 100 Participant-years for Hospitalized Virologically-Confirmed Dengue (VCD) Cases Due to Any and Each Serotype Following Vaccination With Either CYD Dengue Vaccine or Placebo in the Previous Study (CYD23) | Control Group | Serotype 4 | 0.3 | 95% Confidence Interval 0.1 to 0.5 | Events per 100 participant-years |
Event Rate Per 100 Participant-years for Hospitalized Virologically-Confirmed Dengue (VCD) Cases Due to Any and Each Serotype Following Vaccination With Either CYD Dengue Vaccine or Placebo in the Previous Study (CYD23) | CYD Dengue Vaccine Group | Unserotyped | 0.0 | 95% Confidence Interval 0.0 to 0.0 | Events per 100 participant-years |
Event Rate Per 100 Participant-years for Hospitalized Virologically-Confirmed Dengue (VCD) Cases Due to Any and Each Serotype Following Vaccination With Either CYD Dengue Vaccine or Placebo in the Previous Study (CYD23) | Control Group | Unserotyped | 0.1 | 95% Confidence Interval 0.0 to 0.2 | Events per 100 participant-years |
| Number of Hospitalized VCD Cases Due to Any and Each Serotype (1, 2, 3 and 4) Following Vaccination With Either CYD Dengue Vaccine or a Placebo in a Previous Study (CYD23) | CYD Dengue Vaccine Group | Cases: Any of the 4 Serotypes | 85 | Cases | |
| Number of Hospitalized VCD Cases Due to Any and Each Serotype (1, 2, 3 and 4) Following Vaccination With Either CYD Dengue Vaccine or a Placebo in a Previous Study (CYD23) | Control Group | Cases: Any of the 4 Serotypes | 46 | Cases | |
| Number of Hospitalized VCD Cases Due to Any and Each Serotype (1, 2, 3 and 4) Following Vaccination With Either CYD Dengue Vaccine or a Placebo in a Previous Study (CYD23) | CYD Dengue Vaccine Group | Cases: Serotype 1 | 21 | Cases | |
| Number of Hospitalized VCD Cases Due to Any and Each Serotype (1, 2, 3 and 4) Following Vaccination With Either CYD Dengue Vaccine or a Placebo in a Previous Study (CYD23) | Control Group | Cases: Serotype 1 | 11 | Cases | |
| Number of Hospitalized VCD Cases Due to Any and Each Serotype (1, 2, 3 and 4) Following Vaccination With Either CYD Dengue Vaccine or a Placebo in a Previous Study (CYD23) | CYD Dengue Vaccine Group | Cases: Serotype 2 | 29 | Cases | |
| Number of Hospitalized VCD Cases Due to Any and Each Serotype (1, 2, 3 and 4) Following Vaccination With Either CYD Dengue Vaccine or a Placebo in a Previous Study (CYD23) | Control Group | Cases: Serotype 2 | 11 | Cases | |
| Number of Hospitalized VCD Cases Due to Any and Each Serotype (1, 2, 3 and 4) Following Vaccination With Either CYD Dengue Vaccine or a Placebo in a Previous Study (CYD23) | CYD Dengue Vaccine Group | Cases: Serotype 3 | 21 | Cases | |
| Number of Hospitalized VCD Cases Due to Any and Each Serotype (1, 2, 3 and 4) Following Vaccination With Either CYD Dengue Vaccine or a Placebo in a Previous Study (CYD23) | Control Group | Cases: Serotype 3 | 10 | Cases |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01983553/results